Pharmacology News and Research

Latest Pharmacology News and Research

Odyssey Thera receives US patent for application of contextual high-content assays to diverse biological events

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

iOWH, Center for World Health and Medicine partner to combat childhood diarrhea

The Center for World Health and Medicine at Saint Louis University and the Institute for OneWorld Health have established a joint research agreement to develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5.

4 May 2011

PAREXEL third quarter revenue increases 3.5% to $301.4 million

PAREXEL International Corporation today announced its financial results for the third quarter ended March 31, 2011.

From Parexel 3 May 2011

Study explores link between infants' daily growth and sleep

Science is finally confirming what grandma knew all along: infants wake up taller right after they sleep.

2 May 2011

Increased sleep duration is associated with growth spurts in infants

A study in the May 1 issue of the journal Sleep is the first to show that increased bursts of sleep among infants are significantly associated with growth spurts in body length.

2 May 2011

Centocor Ortho Biotech Products withdraws NDA for trabectedin for treatment of women with ROC

Centocor Ortho Biotech Products, L.P., today announced that it has voluntarily withdrawn the New Drug Application for trabectedin for the treatment of women with recurrent ovarian cancer. The withdrawal is based on the U.S. Food and Drug Administration's recommendation that an additional Phase 3 study be conducted to obtain approval.

30 Apr 2011

Melatonin can help fight obesity and risks associated with it

University of Granada researchers have proven that melatonin -a natural hormone produced by the body- helps in controlling weight gain -even without reducing the intake of food-, improves blood lipid profile -as it reduces triglicerids-, increases HDL cholesterol and reduces LDL cholesterol.

29 Apr 2011

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company's proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant funding by the Massachusetts Life Sciences Center.

29 Apr 2011

Special-focus on postoperative cognitive dysfunction in older adults

Postoperative cognitive dysfunction (POCD) refers to a "mild but possibly long-lasting cognitive fogginess" occurring after surgery and anesthesia. The May issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), presents a special-focus section on POCD in older adults—including the possible causes and preoperative evaluation of POCD risk.

28 Apr 2011

Softgels as effective as tablets in delivering folic acid

Folic acid, an essential vitamin formulated to be part of a multivitamin + DHA liquid softgel capsule, is absorbed and available within the body in amounts similar to folic acid formulated for solid tablets, according to a study presented in a late breaking session at the Experimental Biology (EB) 2011 annual meeting.

28 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Study clarifies ginkgo's pain-reducing effects

Experiments in rats show that a standardized ginkgo extract—injected either into the spinal canal or directly into the injured area—effectively reduces inflammation and some types of pain, according to a report in the May issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

28 Apr 2011

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Cancer researchers at hundreds of sites nationwide are about to launch a SWOG-led clinical trial that could keep thousands of breast cancer patients from getting chemotherapy that is unlikely to do them any good.

27 Apr 2011

ISC-4 topical compound may prevent skin cancer lesion formation

While incidents of melanoma continue to increase despite the use of sunscreen and skin screenings, a topical compound called ISC-4 may prevent melanoma lesion formation, according to Penn State College of Medicine researchers.

27 Apr 2011

A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV).

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

Research sheds light on molecular movements of neural transporters

A team of scientists from Columbia University College of Physicians and Surgeons and Weill Cornell Medical College has shed light on the molecular workings of transporter proteins, molecular machines embedded in the cell membranes of neurons that modulate the transfer of signals between cells and recycle neurotransmitters.

25 Apr 2011

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo Company, Limited, announced today that the company has received its first marketing approval for LIXIANA 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

22 Apr 2011